紫杉醇加吉西他滨治疗蒽环类耐药的晚期乳腺癌

Pacilitaxel in association with gemcitabine for anthracycine-resistant advanced breast cancer

目的观察紫杉醇联合吉西他滨方案治疗蒽环类耐药性晚期乳腺癌的疗效与安全性。方法2000年5月至2004年8月以本法治疗蒽环类耐药性晚期乳腺癌26例,每例均化疗2～3周期。结果26例中完全缓解3例(11.5%),部分缓解11例(42.3%),无变化8例(30.8%),疾病进展4例(15.4%),总有效率53.8%,中位生存时间18个月,中位肿瘤进展时间7个月。不良反应主要表现为骨髓抑制、肝功能损害、脱发、黏膜炎、周围神经毒性。结论紫杉醇和吉西他滨联合方案治疗蒽环类耐药性晚期乳腺癌疗效较好,毒性反应较轻,是蒽环类耐药性乳腺癌的有效解救治疗方案。

Objective To evaluate the effect and safety of combined therapy of paclitaxel and gemcitabine for anthraeycine（ ANT）-resistant advanced breast cancer（ABC）. Methods From May 2000 to Aug 2004,twenty six patients with ANT-resistant ABC were treated with this combined regime. The median chemotherapy cycles were 2.5 （ range from 2 to 3 cycles）. Results Of 26 patients, there were 3 complete （ 11.5% ） and 11 partial（42.3% ） responses for an overall response rate of 53.8%. Eight cases remained stable （30. 8% ） and 4 progressive （ 15.4% ）. The median survival time was 18 months. The median time to progression was 7 months. The main toxic reaction included bone marrow depression, liver function damage, alopecia, mucositis and peripheral neurotoxicity. Conclusions Combined medication of gemcitabine and paclitaxel is effective in therapy of ANT-resistant advanced breast cancer with acceptable toxicity.